Jason Mouabbi, MD

This segment emphasizes the need to ensure equitable access to novel HER2-targeted therapies through financial and logistical support, accurate biomarker testing, and effective knowledge dissemination to community clinicians.

This segment emphasizes that multidisciplinary collaboration and survivorship planning are essential to safely deliver HER2-targeted therapies and support long-term patient outcomes.

Clinicians show how to tailor HER2 treatment beyond guidelines, using proactive education and monitoring to curb ADC/TKI toxicities.

Infusion bottlenecks, prior authorizations and travel barriers limit access to new HER2 therapies; upcoming trials test better sequencing and equity.

Experts weigh HER2+ metastatic options after T‑DXd, balancing tucatinib CNS benefit, ADC‑after‑ADC evidence, and patient toxicity or comorbidities.

Experts weigh how early HER2 escalation with T‑DXd reshapes metastatic sequencing, with tucatinib options and APHINITY’s long-term signals.

Experts unpack second-line HER2+ breast cancer choices, why T-DXd leads, and when T-DM1 or tucatinib matters—especially with brain mets.

Experts discuss the sequencing of antibody-drug conjugates in breast cancer treatment, exploring optimal strategies and emerging clinical data.

Explore the promising role of trastuzumab deruxtecan in treating HER2-low triple-negative breast cancer, highlighting key trial findings and expert insights.

In this segment, Dr. Jason Mouabbi and Dr. Bardia explore the growing importance of ESR1 mutations in the management of ER-positive, HER2-negative metastatic breast cancer, particularly after progression on CDK4/6 inhibitor–based therapy.

Dr. Aditya Bardia provides an overview of the current standard of care in the first-line setting, emphasizing the established role of endocrine therapy combined with CDK4/6 inhibitors.

It seems there is no text provided for summarization. Please share the content you'd like summarized, and I'll be happy to help!

Dr. Tarantino discusses the promising results of the Trodelvy breast cancer study, highlighting its impact on treatment for high-risk patients.

Dr. Yuan discusses the ASCENT-03 trial's efficacy, crossover implications, and safety data for sacituzumab govitecan in cancer treatment.

It seems there is no text provided for summarization. Please provide the text you'd like summarized, and I'll be happy to help!

It seems there is no text provided for summarization. Please provide the text you'd like summarized, and I'll be happy to help!

Explore the latest advancements in clinical trials for early-stage triple-negative breast cancer, focusing on promising antibody-drug conjugates (ADCs).

Discover the promising advancements in TROP2-targeted antibody-drug conjugates for treating triple-negative and hormone-positive breast cancer.

Explore the evolving treatment landscape for early-stage triple-negative breast cancer, highlighting innovative therapies and clinical trial insights.

Jason Aboudi Mouabbi, MD, discussed the importance of using ctDNA testing to inform treatment decision-making across breast cancer populations.

Explore the evolving treatment landscape for early-stage triple-negative breast cancer, highlighting innovative therapies and clinical trial insights.

Explore the latest advancements in antibody-drug conjugates for treating triple-negative breast cancer, addressing critical challenges and innovations.

Jason A. Mouabbi, MD, discusses the role of FES-PET/CT imaging in the diagnosis of lobular breast cancer.

Dr Mouabbi highlights the ways that ctDNA has evolved from a research tool to a potential clinical decision-making aid in breast cancer.

Experts discuss the transformative impact of antibody-drug conjugates (ADCs) in cancer treatment, emphasizing their growing role and the need for oncologists to adapt.

Experts discuss the need for better biomarker testing in ADC trials to ensure more patients benefit from targeted therapies.

Experts discuss the potential of maintenance strategies for antibody-drug conjugates in breast cancer, aiming to enhance patient outcomes and manage toxicity.

Explore the innovative world of antibody-drug conjugates, revolutionizing cancer treatment with targeted therapies and reduced side effects.

Explore the evolving landscape of antibody-drug conjugates (ADCs) for breast cancer treatment and the strategic sequencing of therapies.

Explore the latest findings on Phase 3 trials for metastatic triple-negative breast cancer, highlighting treatment efficacy and toxicity profiles.